Edwards inks $400m share repurchase deal

Edwards Lifesciences (NYSE:EW) said today it inked a deal to repurchase an aggregate of $400 million in its common shares.

Under terms of the new share repurchasing deal, Edwards said it will receive approximately 2.5 million shares this month, with the final number of shares to be repurchased based on the volume weighted average share price during the term of the agreement.

Edwards said that as of March 31, it had approximately $1.3 billion authorization remaining on a share repurchase program approved by its board of directors, according to an SEC filing.

Yesterday, Edwards said it won CE Mark approval in the European Union for its Cardioband transcatheter tricuspid valve reconstruction system, touting it as the first commercially cleared transcath therapy for treating tricuspid heart valve disease.

The post Edwards inks $400m share repurchase deal appeared first on MassDevice.

from MassDevice https://ift.tt/2reFmjc